Merck & Co. (NYSE:MRK) is a prominent American multinational pharmaceutical company many investors know for its brand-name ...

Merck on Tuesday missed earnings estimates, lowered its guidance for this year’s earnings, and withdrew a target for sales of ...

The continued decline of Merck & Co.’s HPV vaccine Gardasil in China has come to a head as the New Jersey drug giant is ...

Pfizer and Merck, ostensibly beleaguered drugmakers, have seen their shares battered despite reporting strong earnings.

Merck posted Q4 sales of $15.62 billion, driven by Keytruda's 19% growth. FY25 guidance lags estimates, citing Gardasil ...

Merck (MRK) shares drop 8% premarket as 2025 outlook falls short of Wall Street estimates, despite beating Q4 expectations ...

Merck swung to a fourth-quarter profit as sales grew and even exceeded Wall Street’s estimates, boosted in part by the ...

Merck’s full-year 2025 revenue guidance fell short of what some analysts were expecting, at a range of $64.1 billion to $65.6 ...

(Reuters) - Merck said it will pause shipments of Gardasil to China through at least mid-year, as continued weak demand for ...

Merck said it will pause shipments of Gardasil to China through at least mid-year, as continued weak demand for the HPV vaccine there is expected to hurt 2025 revenue, but it still posted a strong ...